Zydus Cadila’s COVID vaccine has shown an efficacy rate of 66.6 percent for symptomatic RT-PCR positive cases, in over 28,000 volunteers, according to an interim analysis of Phase III clinical trials. After the third dose of the vaccine, it was noted that no common cases of COVID were observed in the vaccine beneficiaries.
In addition, no serious illness or death was reported in people who received the second dose of the vaccine. However, data from the phase three trial has not yet been peer-reviewed.
With regard to the current development, Pankaj R Patel, President, Zydus Group, said, “We are extremely pleased that our efforts to develop a safe, well-tolerated and efficacious vaccine to fight COVID-19 have come together with ZyCoV. have become a reality. -D. Creating the world’s first DNA vaccine at such a critical juncture and despite all the challenges is a tribute to Indian research scientists and their spirit of innovation. I would like to thank the Department of Biotechnology, Government of India for their support in this mission of self-reliant India and the Indian Vaccine Mission for COVID protection.
.